Literature DB >> 20002077

Obesity treatment: novel peripheral targets.

Benjamin C T Field1, Owais B Chaudhri, Stephen R Bloom.   

Abstract

Our knowledge of the complex mechanisms underlying energy homeostasis has expanded enormously in recent years. Food intake and body weight are tightly regulated by the hypothalamus, brainstem and reward circuits, on the basis both of cognitive inputs and of diverse humoral and neuronal signals of nutritional status. Several gut hormones, including cholecystokinin, glucagon-like peptide-1, peptide YY, oxyntomodulin, amylin, pancreatic polypeptide and ghrelin, have been shown to play an important role in regulating short-term food intake. These hormones therefore represent potential targets in the development of novel anti-obesity drugs. This review focuses on the role of gut hormones in short- and long-term regulation of food intake, and on the current state of development of gut hormone-based obesity therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002077      PMCID: PMC2810794          DOI: 10.1111/j.1365-2125.2009.03522.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  207 in total

Review 1.  Obesity as a medical problem.

Authors:  P G Kopelman
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

2.  The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33.

Authors:  J F Rehfeld; G Sun; T Christensen; J G Hillingsø
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

3.  Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.

Authors:  R Perfetti; J Zhou; M E Doyle; J M Egan
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

4.  Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice.

Authors:  N Ueno; A Inui; M Iwamoto; T Kaga; A Asakawa; M Okita; M Fujimiya; Y Nakajima; Y Ohmoto; M Ohnaka; Y Nakaya; J I Miyazaki; M Kasuga
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

5.  Ghrelin induces adiposity in rodents.

Authors:  M Tschöp; D L Smiley; M L Heiman
Journal:  Nature       Date:  2000-10-19       Impact factor: 49.962

6.  Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction.

Authors:  R A Liddle; I D Goldfine; M S Rosen; R A Taplitz; J A Williams
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

7.  Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans.

Authors:  Y Date; M Kojima; H Hosoda; A Sawaguchi; M S Mondal; T Suganuma; S Matsukura; K Kangawa; M Nakazato
Journal:  Endocrinology       Date:  2000-11       Impact factor: 4.736

8.  Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice.

Authors:  A Asakawa; A Inui; N Ueno; M Fujimiya; M A Fujino; M Kasuga
Journal:  Peptides       Date:  1999-12       Impact factor: 3.750

9.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

10.  Capsaicin pretreatment attenuates suppression of food intake by cholecystokinin.

Authors:  R C Ritter; E E Ladenheim
Journal:  Am J Physiol       Date:  1985-04
View more
  20 in total

1.  Editors' pick 2009.

Authors:  A Somogyi; Y K Loke; A Ferro; L D Lewis; A F Cohen; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

Review 2.  Antipsychotic drugs and obesity.

Authors:  Christoph U Correll; Todd Lencz; Anil K Malhotra
Journal:  Trends Mol Med       Date:  2010-12-22       Impact factor: 11.951

3.  Editorial for BJCP Special Obesity Edition.

Authors:  Adrian Park
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 4.  Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?

Authors:  Carmine Finelli; Maria Carmela Padula; Giuseppe Martelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

Review 5.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 6.  Anti-obesogenic and antidiabetic effects of plants and mushrooms.

Authors:  Jan Martel; David M Ojcius; Chih-Jung Chang; Chuan-Sheng Lin; Chia-Chen Lu; Yun-Fei Ko; Shun-Fu Tseng; Hsin-Chih Lai; John D Young
Journal:  Nat Rev Endocrinol       Date:  2016-09-16       Impact factor: 43.330

7.  Diet-induced obesity blunts the behavioural effects of ghrelin: studies in a mouse-progressive ratio task.

Authors:  Beate C Finger; Timothy G Dinan; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2011-09-03       Impact factor: 4.530

8.  Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome.

Authors:  Haifeng Ye; Ghislaine Charpin-El Hamri; Katharina Zwicky; Matthias Christen; Marc Folcher; Martin Fussenegger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

9.  Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity.

Authors:  Alexandre Dal-Pan; Stéphane Blanc; Fabienne Aujard
Journal:  BMC Physiol       Date:  2010-06-22

Review 10.  Obesity vaccines.

Authors:  Mariana P Monteiro
Journal:  Hum Vaccin Immunother       Date:  2013-12-23       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.